NewAmsterdam Pharma Co N.V. (NAMS) Form 8-K — Jun 3, 2026
NewAmsterdam Pharma Co N.V. (NAMS) held its 2026 annual general meeting on June 2, 2026, where shareholders approved the adoption of the 2026 Employee Stock Purchase Plan (ESPP). The ESPP allows eligible employees to purchase up to 1,150,000 ordinary shares at a 15% discount to the market price, with purchase periods generally lasting six months. Shareholders also ratified the selection of Deloitte as the independent auditor for the fiscal year ending December 31, 2026, and approved the re-appointment of non-executive directors John W.
Key figures
- Shares Outstanding
- 116,903,979
- Espp discount
- 15%
- Quorum shares
- 91,538,612
- Espp max shares
- 1,150,000
- Quorum percentage
- 78.3%
Price after filing
Close on the filing date to close N calendar days later (from $32.11). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.